dc-cik联合化疗治疗晚期胃癌的近期疗效观察

《dc-cik联合化疗治疗晚期胃癌的近期疗效观察》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、DC-CIK联合化疗治疗晚期胃癌的近期疗效观察【摘要】目的探讨树突状细胞（dendriticcell，DC）共培养细胞因子诱导的杀伤细胞（cytokine-inducedkiller,CIK）联合化疗治疗晚期胃癌患者的近期疗效。方法选取28例确诊的晚期胃癌患者采用DC-CIK联合化疗为联合治疗组，选取临床资料相近的同期进行单纯化疗的28例的晚期胃癌患者为对照组，观察两组患者治疗前后外周血中T细胞亚群,细胞因子及卡氏评分（KarnofskyKPS）的变化，临床疗效，并记录其不良反应。结果联合治疗组患者治疗后CD3+,CD4+,CD56+和CD

2、4+/CD8+的比例无明显变化（P＞0.05），对照组CD3+,CD4+和CD4+/CD8+的比例治疗后明显下降（P<0.05）；联合治疗组的细胞因子IL-12和IFN-γ的水平治疗后有所上升（P<0.05），治疗组IL-2,IL-12和TNF-α的水平治疗后有所下降（P<0.05）。联合治疗组的疾病控制率为78.6%，与对照组的53.6%差别有统计学意义（P<0.05），KPS评分总提高率为82.14%，与对照组的57.14%差别有统计学意义（P<0.05），结论DC-CIK联合化疗与对照组比能提高患者的免疫功能及生活质量，DC-CIK免

3、疫治疗联合化疗可望成为胃癌有效的过继免疫治疗方法。【关键词】树突状细胞;细胞因子诱导的杀伤细胞;胃癌;过继免疫治疗Short-termcurativeefficacyofDC-CIKcell-therapycombinedwithchemotherapyonpatientswithadvancedgastriccancer【Abstract】ObjectiveToinvestigateclinicaleffectsofdendriticcells(DC)co-culturedwithcytokineinducedkillercells(CI

4、K)combinedwithchemotherapyonpatientswithadvancedgastriccancer.Methodstwenty-eightpatientswithadvancedgastriccancerweretreatedwithDC-CIKcombinedwithchemotherapyweretakenasthecombinedtreatmentgroup,anothertwenty-eightpatientswhoweretreatedwithchemotherapyaloneduringthesamepe

5、riodweretakenascontrol.Tlymphocytesubtypes，intra-cellularcytokinesinperipheralbloodofthepatientsandPerformanceStatus(KPS)werecomparedbetweenthetwogroups.Theclinicaleffectswereanalysed.Thesafetywereobserved.ResultsTheratiosofCD3+,CD4+,CD56+andCD4+/CD8+werenotchangeobviously

6、incombinedtreatmentgroupanddecreasedincontrolgroupaftertreatment,whichshowedsignificantstatisticaldifference(P<0.05).TheIL-12andIFN-γwereincreasedaftertreatmentincombinedtreatmentgroup,(P<0.05).TheIL-2,IL-12andTNF-αweredecreasedincontrolgroupaftertreatment,(P<0.05).Thedise

7、asecontrolrate(DCR)ofcombinedtherapygroupandcontrolgroupwere78.6%and53.6%respectivelyshowingsignificantdifference(P<0.05).TheeffectiverateofKPSwere82.14%and57.14%respectivelyshowingsignificantdifference(P<0.05).Conclusion:DC-CIKcellscombinedwithchemotherapycanimproveimmune

8、functionsandelevatelifequalityofthepatients.DC-CIKcellscombinedwithchemotherapyislikelyto